Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 2, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	24	66	228	131	219	147
Market Cap Growth	-70.87%	-70.87%	73.64%	-40.03%	49.16%	-26.16%
Enterprise Value	-16	19	157	9	17	60
Last Close Price	0.31	0.93	3.22	1.86	3.21	2.31
PE Ratio	-	-	-	-	1.82	-
PS Ratio	38.80	117.14	580.59	87.22	1.05	11.61
PB Ratio	0.32	0.97	2.59	0.99	1.22	3.36
P/TBV Ratio	0.97	0.97	2.60	0.99	1.22	3.38
P/FCF Ratio	-	-	-	1.85	-
P/OCF Ratio	-	-	-	1.84	-
EV/Sales Ratio	32.98	32.98	400.05	6.30	0.08	4.73
EV/EBITDA Ratio	-	-	-	0.14	-
EV/EBIT Ratio	-	-	-	0.14	-
EV/FCF Ratio	-	-	-	0.14	-
Debt / Equity Ratio	0.22	0.22	0.18	0.13	-	-
Asset Turnover	0.01	0.01	0.00	0.01	1.54	0.16
Quick Ratio	5.04	5.04	9.23	18.45	12.69	3.27
Current Ratio	5.32	5.32	9.55	18.79	12.87	3.39
Return on Equity (ROE)	-33.88%	-33.88%	-47.57%	-34.72%	109.98%	-142.60%
Return on Assets (ROA)	-30.90%	-30.90%	-24.05%	-19.85%	57.40%	-64.93%
Return on Capital (ROIC)	-39.07%	-39.07%	-28.49%	-21.13%	69.51%	-89.56%
Return on Capital Employed (ROCE)	-	-	-	-	69.10%	-
Earnings Yield	-118.00%	-39.87%	-23.00%	-41.33%	56.20%	-55.30%
FCF Yield	-254.53%	-84.50%	-20.13%	-43.07%	54.18%	-35.29%
Buyback Yield / Dilution	-0.46%	-0.46%	-0.22%	-3.46%	-16.45%	-49.05%

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q